5/6/2021  5:42:48 PM Chg. -0.30 Volume Bid6:30:00 PM Ask6:30:00 PM Market Capitalization Dividend Y. P/E Ratio
153.00GBX -0.20% 914,793
Turnover(GBP): 1.36 mill.
130.00Bid Size: 5,000 -Ask Size: - 1.12 bill.GBP - -

Business description

Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy, health policy and evidence-based best practice models that have revolutionized modern addiction treatment. The name is the fusion of the words individual and endeavor, and the tagline “Focus on you” makes the company’s commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease.
 

Management board & Supervisory board

CEO
Mark Crossley
Management board
Ryan Preblick, Christian Heidbreder, Cindy Cetani, Hillel West, Jon Fogle, Kathryn Hudson, Richard Simkin, Ryan Preblick
Supervisory board
Daniel J. Phelan, Daniel Tassé, Dr. A. Thomas McLellan, Graham Hetherington, Kathryn Hudson, Lorna Parker, Mark Crossley, Peter Bains, Ryan Preblick
 

Company data

Name: Indivior PLC
Address: 103-105 Bath Road,UK-Slough, SL1 3UH UK, Berkshire
Phone: +44-1753-217800
Fax: +44-1753-217899
E-mail: -
Internet: indivior.com/
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 56.31%
IPO date: -

Investor relations

Name: Kathryn Hudson
IR phone: +1-804-423-8916
IR Fax: -
IR e-mail: investorrelations@indivior.com

Company calendar

CW 31 | 7/29/2021 Interim Report 2nd Quarter/6 Months
CW 44 | 10/28/2021 Interim Report 3rd Quarter/9 Months
 

Main Shareholders

Freefloat
 
56.31%
Scopia Capital Management
 
16.61%
Standard Life Aberdeen
 
9.99%
Old Mutual Global Investors (UK) Limited
 
8.02%
Kairos Capital Management
 
5.13%
Newtyn Management
 
3.94%